GW Pharmaceuticals seeks European approval for cannabinoid spray

By Lisa Kerner

Charlotte, N.C., Sept. 5 - GW Pharmaceuticals plc filed a regulatory submission in the United Kingdom, Spain, Denmark and Netherlands for its cannabinoid spray medicine, Sativex, for the symptomatic relief of spasticity in people with multiple sclerosis.

Under a decentralized procedure, acceptance by the United Kingdom would lead to the simultaneous approval of the Sativex filing in the other three countries.

Upon approval, Sativex will be marketed in the United Kingdom by Bayer HealthCare and by Almirall throughout Europe.

GW Pharmaceuticals is based in Porton Down, U.K.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.